Impact of Neuropathic Post-Zosterian Pain on the Cognition
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00989040|
Recruitment Status : Completed
First Posted : October 2, 2009
Last Update Posted : January 30, 2012
|Condition or disease||Intervention/treatment||Phase|
|Neuropathic Post-zosterian Pain Cognition||Drug: usual treatment: Versatis||Phase 1|
|Study Type :||Observational|
|Actual Enrollment :||100 participants|
|Observational Model:||Case Control|
|Official Title:||Impact of Neuropathic Post-zosterian Pain on the Cognition (NPZ and Cognition)|
|Study Start Date :||March 2009|
|Primary Completion Date :||June 2009|
|Study Completion Date :||September 2009|
Drug: usual treatment: Versatis
- To explore if the cognition is failed in treated patients suffering of neuropathic postzosteria pain.
- To see if treated patients with patch (Versatis®) have better cognition than treated patients without patch.
- The principal outcome is to explore if the cognition is failed in treated patients suffering of neuropathic post-zosteria pain. [ Time Frame: at day 1 ]
- Study if treated patients with patch (Versatis®) have better cognition than treated patients without patch. [ Time Frame: at day 1 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00989040
|Clermont-Ferrand, France, 63003|
|Principal Investigator:||Claude Dubray, PUPH||CIC-CPC Clermont-Ferrand|